Commercialization
-
hapabapa via Getty Images
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
By Amy Baxter • April 21, 2025 -
Sedat Suna via Getty Images
Novartis scores NFL deal to tackle health outcomes
The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.
By Amy Baxter • April 17, 2025 -
Permission granted by Novavax
ProfileThe industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
By Alexandra Pecci • March 25, 2025 -
Stock via Getty Images
Pricing transparency is in the spotlight — and that could be good news for drugmakers
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
By Michael Gibney • March 11, 2025 -
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025 -
Drew Angerer via Getty Images
Challenges mount for vaccine makers
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.
By Amy Baxter • Feb. 19, 2025 -
Stock via Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
By Michael Gibney • Feb. 13, 2025 -
Stock via Getty Images
The kids are alright: How pharma can make inroads with Gen Z
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
By Amy Baxter • Feb. 12, 2025 -
Permission granted by Fractyl Health
Q&A // Biotech SpotlightBeyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.
By Amy Baxter • Feb. 10, 2025 -
Permission granted by Bristol Myers Squibb
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
By Jacob Bell • Feb. 7, 2025 -
cagkansayin via Getty Images
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.
By Michael Gibney • Feb. 6, 2025 -
Permission granted by Klein Hersh
Executive hiring changes reflect a broader biotech comeback
Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.
By Alexandra Pecci • Jan. 29, 2025 -
Stock via Getty Images
Innovate or perish: Industry’s evolution leaves little room for me-too approaches
Novel drug approvals have set the stage for more breakthroughs in pharma.
By Amy Baxter • Updated Jan. 22, 2025 -
Stock via Getty Images
In pharma’s competitive climate, companies need evidence beyond clinical trials
Early planning and market research are crucial in an era of rising cost pressures.
By Kelly Bilodeau • Jan. 21, 2025 -
Sundry Photography via Getty Images
Merck is broadening its pipeline as Keytruda’s patent cliff looms
Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.
By Alexandra Pecci • Jan. 14, 2025 -
Stock via Getty Images
The ability to pivot will be ‘key’ as pharma’s tariff threat looms
Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.
By Kelly Bilodeau • Jan. 13, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Sarah Silbiger via Getty Images
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
By Ned Pagliarulo • Dec. 20, 2024 -
Scott Olson via Getty Images
Big Pharma’s new DTC play: partnering with digital health providers
The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.
By Amy Baxter • Dec. 18, 2024 -
Stock via Getty Images
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.
By Amy Baxter • Dec. 9, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Permission granted by Ron Tilles, Kevin Mercuri
ProfileLeft to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
By Michael Gibney • Nov. 14, 2024 -
Stock via Getty Images
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
By Amy Baxter • Nov. 13, 2024 -
Permission granted by Pfizer
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
By Kelly Bilodeau • Nov. 12, 2024
